Literature DB >> 21733282

Rapid-acting antidepressant strategies: mechanisms of action.

Blynn G Bunney1, William E Bunney.   

Abstract

Current antidepressants are ineffective in many depressed patients. Thus there is an urgent need to develop treatment strategies which have significantly faster response, can be sustained and have minimal side-effects. This paper reviews clinical data, potential biomarkers, mechanisms of action and future research directions for two proven strategies that produce marked improvement in severe depressive symptoms within 48 h, ketamine and sleep deprivation therapy (SDT). These treatments provide unequivocal evidence that the depressive process can be rapidly reversed in a subgroup of patients. Seventeen ketamine studies in over 150 patients showed a rapid response. Low-dose intravenous ketamine produced mild psychotomimetic effects but response has not been effectively sustained. SDT has been investigated in over 60 studies with a 40-60% response rate within 48 h. Although SDT is often used in Europe to initiate a rapid response, it is less utilized within the USA, in part, because it has a short duration when administered alone. We review data concerning chronotherapeutic strategies of bright-light therapy (BLT) and sleep-phase advance (SPA) which successfully sustain the antidepressant efficacy of SDT. Evidence is further discussed that a significant group of mood disorders have abnormal circadian rhythms which are known to be controlled by clock genes. It is hypothesized that chronotherapeutic manipulations can reset clock genes and thus, abnormalities in circadian rhythms. Further findings are reviewed that ketamine, in addition to its role as an NMDA antagonist, can also alter circadian rhythms. Thus, ketamine may share a critical mechanism with SDT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733282     DOI: 10.1017/S1461145711000927

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  32 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

2.  Evidence for alterations of the glial syncytial function in major depressive disorder.

Authors:  Adriana Medina; Stanley J Watson; William Bunney; Richard M Myers; Alan Schatzberg; Jack Barchas; Huda Akil; Robert C Thompson
Journal:  J Psychiatr Res       Date:  2015-10-23       Impact factor: 4.791

Review 3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.

Authors:  Arun V Ravindran; Lynda G Balneaves; Guy Faulkner; Abigail Ortiz; Diane McIntosh; Rachel L Morehouse; Lakshmi Ravindran; Lakshmi N Yatham; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 4.  Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.

Authors:  B G Bunney; J Z Li; D M Walsh; R Stein; M P Vawter; P Cartagena; J D Barchas; A F Schatzberg; R M Myers; S J Watson; H Akil; W E Bunney
Journal:  Mol Psychiatry       Date:  2014-11-04       Impact factor: 15.992

5.  Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.

Authors:  Wallace C Duncan; Elizabeth D Ballard; Carlos A Zarate
Journal:  Handb Exp Pharmacol       Date:  2019

Review 6.  Bright light therapy for depression: a review of its effects on chronobiology and the autonomic nervous system.

Authors:  Mark A Oldham; Domenic A Ciraulo
Journal:  Chronobiol Int       Date:  2014-01-07       Impact factor: 2.877

7.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

Review 8.  Serotonin and beyond: therapeutics for major depression.

Authors:  Pierre Blier; Mostafa El Mansari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

9.  Circadian patterns of gene expression in the human brain and disruption in major depressive disorder.

Authors:  Jun Z Li; Blynn G Bunney; Fan Meng; Megan H Hagenauer; David M Walsh; Marquis P Vawter; Simon J Evans; Prabhakara V Choudary; Preston Cartagena; Jack D Barchas; Alan F Schatzberg; Edward G Jones; Richard M Myers; Stanley J Watson; Huda Akil; William E Bunney
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

10.  Rapid antidepressant effects: moving right along.

Authors:  K Martinowich; D V Jimenez; C A Zarate; H K Manji
Journal:  Mol Psychiatry       Date:  2013-05-21       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.